Skip to content
Review Open access

p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications.

Sep 2026 · Cancer Treatment Reviews · Vol 150, pp. 103212 · 0 citations · 88 references
Medicine

TL;DR

The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed, and a timely and cohesive synthesis of a rapidly evolving field is offered.

Abstract

Non-small cell lung cancer (NSCLC) harbouring mutations in the epidermal growth factor receptor (EGFR) represents a well-defined molecular subset that is amenable to targeted therapies. However, clinical heterogeneity in treatment response and resistance highlights the critical need for a deeper understanding of co-occurring genetic alterations. Among these, TP53 mutations are the most frequent co-mutations observed in EGFR-mutant NSCLC and are increasingly recognized for their prognostic and predictive relevance. With the emergence of next-generation sequencing in routine diagnostics and the growing arsenal of targeted therapies, the time is ripe to comprehensively assess how p53 co-mutations shape tumor biology, influence drug resistance, and impact patient outcomes. This review integrates recent mechanistic insights with therapeutic strategies and emerging clinical data, offering a timely and cohesive synthesis of a rapidly evolving field. The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed.

Read PDF

Similar papers

Review Open access Oct 2026

A Review of Driver Gene Co-mutations in Prognostic Stratification of Targeted Therapy for Non-Small Cell Lung Cancer

EGFR-TKIs have significantly improved the survival outcomes of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, substantial heterogeneity in treatment efficacy exists among individuals, and conventional single-gene testing has limitations in guiding therapeutic decision-making. This systematic rev...

Yun Feng · 0 citations
Review Sep 2026

Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies.

Triple-negative breast cancer (TNBC) remains a highly aggressive and therapeutically challenging subtype, defined by the absence of oestrogen, progesterone, and HER2 expression. Tumour Protein 53 (TP53) mutations represent the most frequent genetic alteration, occurring in over 80% of cases and driving tumour initiatio...

B. Karikalan, Ye Htut Linn, Shiueh-Lian Mok · 0 citations
Review Sep 2026

Targeting KRAS-Mutant Lung Cancers.

KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.

E. Garbo, P. Scaparone, H. J. Hoe et al. · 0 citations
Case report Open access Oct 2026

Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer

Background Treatment of non-small cell lung cancer (NSCLC) has evolved dramatically over the past decade with the advent of widespread genetic testing, immunotherapy, and targeted therapies. Treatments directed against epidermal growth factor receptor (EGFR) and other driver mutations have reduced toxicity and improved...

Aaron Negin, Kush Sachdeva, J. Weiss · 0 citations
Review Open access Sep 2026

The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine

The complexity of KRAS biology in NSCLC is highlighted and the importance of integrating molecular, epigenetic, and therapeutic insights to advance precision medicine and improve clinical outcomes is underscored.

Jadwiga Gaździcka, K. Gołąbek · 0 citations
Review Open access Sep 2026

Targeted therapy resistance in EGFR-mutant non-small cell lung cancer: Roles of MET, Trop-2-directed antibody–drug conjugates, and molecular monitoring

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC), but acquired resistance remains a major barrier to durable disease control. Objective: This narrative review summarizes the major...

Kai Yan, Ke-Wei Tian, Lai-Ling Du et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.